@article{repository471, journal = {Scientia Pharmaceutica}, publisher = {MDPI}, title = {Quantification of 6-Mercaptopurine and Its Metabolites in Patients with Acute Lympoblastic Leukemia Using Dried Blood Spots and UPLC-MS/MS}, url = {http://www.mdpi.com/2218-0532/86/2/18}, abstract = {This research aimed to quantitatively bioanalyze 6-mercaptopurine (6-MP), 6-methylmercaptopurine (6-MMP), and 6-thioguanosine-50 -monophosphate (6-TGMP) in dried blood spots (DBS) prepared from a small volume of acute lymphoblastic leukemia (ALL) patients. Analytes on the DBS card were extracted using 90\% methanol with 5-fluorouracil (5-FU) as an internal standard. Analytical separation was performed on a Waters Acquity(R) UPLC BEH AMIDA column of 1.7 {\ensuremath{\mu}}m (2.1 {$\times$} 100 mm) with a mobile phase mixture of 0.2\% formic acid in water and 0.1\% formic acid in acetonitrile-methanol, with gradient elution and a flow rate of 0.2 mL/min. Mass detection of 6-MP, 6-MMP, 6-TGMP, and 5-FU showed m/z values of 153.09 {\ensuremath{>}} 119.09, 167.17 {\ensuremath{>}} 126.03, 380.16 {\ensuremath{>}} 168.00, and 129.09 {\ensuremath{>}} 42.05, respectively. This DBS method had a run time of 5 min and yielded a linear calibration curve over a range of 25.5-1020 ng/mL for 6-MP, 6-MMP, and 6-TGMP. Analyte analysis in 22 of 24 ALL patients showed that the measured value of 6-TGMP as an active metabolite was in the range of 29-429 pmol/8 {$\times$} 108 erythrocytes. Five of 22 patients had concentrations in a therapeutic range, which indicates that the treatment is effective, while 17 of 24 patients had concentrations below the therapeutic range, which indicates that a treatment dose adjustment is needed. The measured value of 6-MMP, an inactive metabolite, was in the range of 28-499 pmol/8 {$\times$} 108 erythrocytes, which includes concentrations below the hepatotoxic range. The method employed here can thus be effectively utilized to support therapeutic drug monitoring.}, author = {Supandi Supandi, Supandi} }